Soriot's ship stays the course in first quarter

30 April 2021

Markets welcomed a robust first quarter 2021 results statement from AstraZeneca (LSE: AZN), with the firm reporting revenues of $7.3 billion, an increase of 15% on the same period from last year.

Analysts had expected sales to come in below $7 billion, and the firm’s share price rose 2% on Thursday, before continuing to rise a further 4% to £77.04 on Friday morning.

Earnings per share (EPS) doubled in the quarter, at $1.19, reflecting the benefit from a lower tax rate as a result of a non-taxable gain from the sale of Viela Bio.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK